Sign in

GNPX on Nasdaq

Genprex, Inc.

In its 2026 annual report the company says: “We are a clinical stage gene therapy company pioneering the development of gene-based therapies for large patient populations with unmet medical needs. Our oncology platform utilizes our systemic, non-viral ONCOPREX® Delivery System which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells.”5 It is headquartered in Austin, United States.2 Its shares trade on Nasdaq under the symbol GNPX.2

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with another stock.

  • TickerGNPX on Nasdaq2
  • IndustryPharmaceutical Preparations2
  • HeadquartersAustin, United States2
  • Incorporated inTX3
  • Business address3300 Bee Cave Road Suite 650-227, Austin, Tx 787463
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI549300KS9771JZ2348902
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O The Corporation Trust Company, 19801 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 46721852

See how the biggest companies compare on our leaderboards

We are a clinical stage gene therapy company pioneering the development of gene-based therapies for large patient populations with unmet medical needs. Our oncology platform utilizes our systemic, non-viral ONCOPREX® Delivery System which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells. The product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. Our diabetes technology is designed to work in Type 1 diabetes by transforming alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body’s immune system. In Type 2 diabetes, our technology is believed to work by replenishing and rejuvenating exhausted beta cells that make insulin.5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2024

-1303.0%Return on equity6

Financial statements

Revenue78910$0 in 2024
02020: $0$020202021: $0$020212022: $0$020222023: $0$020232024: $0$02024
Operating income11789106-$21.2M in 2024+98% since 2019
-$40.0M-$30.0M-$20.0M-$10.0M02019: -$10.7M-$10.7M20192020: -$18.0M-$18.0M2020+68%2021: -$20.7M-$20.7M2021+15%2022: -$23.8M-$23.8M2022+15%2023: -$31.1M-$31.1M2023+30%2024: -$21.2M-$21.2M2024−32%
Net income11789106-$21.1M in 2024+98% since 2019
-$40.0M-$30.0M-$20.0M-$10.0M02019: -$10.7M-$10.7M20192020: -$17.9M-$17.9M2020+68%2021: -$20.7M-$20.7M2021+15%2022: -$23.7M-$23.7M2022+15%2023: -$30.9M-$30.9M2023+30%2024: -$21.1M-$21.1M2024−32%

Every line of the income statement as filed: the last 2 fiscal years, latest first.6

Period ending2025-12-312024-12-31
Depreciation$0$6.7K
Research and development$9.4M$10.5M
General and administrative$6.1M$10.6M
Total operating expenses$15.5M$21.2M
Operating loss-$15.5M-$21.2M
Other income$26.9K$63.6K
Other financing costs-$739.9K$0
Realized and unrealized loss-$299-$570
Net loss-$16.2M-$21.1M
Deemed dividend related to warrant modification$0-$277.1K
Net loss attributable to common stockholders-$16.2M-$21.4M
Net loss per share applicable to common stockholders basic and diluted (in dollars per share)-$17.40-$266.89
Weighted average number of common shares basic and diluted (in shares)932.7K shares80.1K shares

Compare Genprex, Inc. with another company

Corporate structure

Genprex, Inc. sits at the top of its group. 2 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Genprex, Inc.

  • Ayrton Capital LLC Filed SCHEDULE 13G/A on Genprex, Inc., latest May 11, 2026 (2 filings since Feb 11, 2026)
  • INTRACOASTAL CAPITAL, LLC Filed SCHEDULE 13G on Genprex, Inc., latest Nov 3, 2025
  • Forsakringsaktiebolaget Avanza Pension Filed SCHEDULE 13G on Genprex, Inc., latest Jan 15, 2025 (2 filings since Oct 3, 2024)
  • Masaya Otsuka Filed SC 13G/A on Genprex, Inc., latest Oct 24, 2024 (2 filings since Oct 22, 2024)
  • CVI Investments, Inc. Filed SC 13G/A on Genprex, Inc., latest Feb 14, 2024 (2 filings since Jul 24, 2023)
  • Genprex, Inc. Austin, Texas, United States
    • Convergen Biotech, Inc. Subsidiary · Delaware, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Genprex, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$06 Dec 31, 2025$06 Dec 31, 2024

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$7.8M6 Dec 31, 2025$1.6M6 Dec 31, 2024+388.9%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$010 Dec 31, 2024$773.5K10 Dec 31, 2023−100.0%

Properties, in its own words

Our principal offices are located at 3300 Bee Cave Road, #650-227, Austin, Texas 78746. We operate primarily as a virtual company, and we believe our current facilities and other facilities available to us are sufficient to meet our current needs and that suitable space will be available as and when needed. We do not own any real property.

Item 2 of the 10-K filed Mar 30, 2026.5

Leadership

Who has led Genprex, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. John Rodney Varner2018–2024
  2. Ryan M. Confer2024–now

Chair

  1. John Rodney Varner2023–2024

President

  1. Julien L. Pham2018–2019
  2. John Rodney Varner2020–2024
  3. Ryan M. Confer2024–now

Chief financial officer

  1. Ryan M. Confer2018–now

Chief operating officer

  1. Julien L. Pham2018–2019
  2. Michael Thomas Redman2020–2021
20202025
Board members and other officers (10)

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • Convergen Biotech, Inc. Delaware4

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Timeline

  1. Aug 18, 20268-K Other events30
  2. Aug 5, 20268-K Listing notice or transfer31
  3. Aug 3, 20268-K Other events32
  4. Jul 30, 20268-K Listing notice or transfer; Other events33
  5. Jul 14, 20268-K Change to shareholders' rights; Bylaws or fiscal year changed; Regulation FD disclosure34
  6. Jun 22, 20268-K Other events35
  7. Jun 18, 20268-K Executive or director change; Shareholder vote36
  8. Jun 12, 20268-K Listing notice or transfer; Other events37
  9. May 26, 20268-K Other events38
  10. May 14, 20268-K Other events39
  11. Apr 30, 20268-K Other events40
  12. Apr 28, 20268-K Other events41
  13. Dec 6, 2024New chief executive Ryan M. Confer becomes CEO14
  14. Mar 29, 2018New chief executive John Rodney Varner becomes CEO15
  15. Apr 1, 2009Founded Genprex, Inc. is founded2

Calendar

Coming up

  1. Nov 13, 2026Reports results for the quarter ending Sep/202642

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

240 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 102 major events, 42 insider forms, 9 large holders, 67 other. The latest 20:

  1. Aug 18, 20268-K EDGAR
  2. Aug 14, 202610-Q EDGAR
  3. Aug 5, 20268-K EDGAR
  4. Aug 3, 20268-K EDGAR
  5. Jul 30, 20268-K EDGAR
  6. Jul 14, 20268-K EDGAR
  7. Jun 26, 2026S-8 EDGAR
  8. Jun 22, 20268-K EDGAR
  9. Jun 18, 20268-K EDGAR
  10. Jun 12, 20268-K EDGAR
  11. Jun 5, 2026S-3 EDGAR
  12. May 26, 20268-K EDGAR
  13. May 14, 20268-K EDGAR
  14. May 13, 202610-Q EDGAR
  15. May 11, 2026SCHEDULE 13G/A EDGAR
  16. Apr 30, 20268-K EDGAR
  17. Apr 29, 2026ARS EDGAR
  18. Apr 29, 2026DEF 14A EDGAR
  19. Apr 28, 20268-K EDGAR
  20. Apr 21, 20268-K EDGAR

The 240 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

3 open-market trades by officers, directors and large owners since October 2021: 2 buys and 1 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Apr 14, 2026LONGNECKER BRENT MDirectorSale18$1.23$22Form 4
Apr 21, 2023Varner John RodneyChairman, President and CEOBuy19,000$1.06$20.1KForm 4
Apr 21, 2023VACZY CATHERINE MEVP GC Chief Strategy OfficerBuy20,000$1.07$21.4KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Ryan M. Confer$480.0K$728.9K48
2025Mark S. Berger$486.5K$688.6K48
2024Chief Medical Officer$486.5K$551.7K48
2024PresidentChief Executive Officer, and Chief Financial Officer$462.5K$541.6K48

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Cheviot Value Management, LLC1,000$5190.0%New
Harbour Investments, Inc.108$560.0%New

13F reports cover disclosed long positions in U.S. stocks only.

Members of Congress who traded it

4 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

DateMemberTradeAmountVs S&P sinceFiling
Feb 5, 2026Tim MooreRepublican, HouseBuy$1,001 - $15,000−108.6%Report
Dec 18, 2025Tim MooreRepublican, HouseBuy$1,001 - $15,000−109.3%Report
Nov 7, 2025Tim MooreRepublican, HouseBuy$1,001 - $15,000−112.6%Report
Oct 29, 2025Tim MooreRepublican, HouseBuy$15,001 - $50,000−110.7%Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

SEC filer profile

How Genprex, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARGenprex, Inc.1
  • CIK0001595248
  • Employer ID (EIN)90-07723475
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company5
  • Incorporated inDelaware5
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address3300 Bee Cave Road Suite 650-227, Austin, TX 787461
  • Phone512-537-79971
  • Shares outstanding819,709 as of Aug 10, 202613
  • Public float$7.5M as of Jun 30, 20255
  • AuditorWithumSmith+Brown, PC, East Brunswick, New Jersey PCAOB ID 100; no auditor attestation of internal control over financial reporting5
  • On EDGAR sinceDec 26, 20131
  • Filings487 in all: 8-K (154), 4 (75), 10-Q (27), CORRESP (23), 424B5 (19), 3 (17), UPLOAD (15), SC 13G (13)1
    All 43 form types

    DEF 14A (11), SC 13G/A (11), EFFECT (10), S-1/A (10), 10-K (9), 424B3 (8), DEFA14A (8), S-1 (8), S-8 (8), D (7), PRE 14A (6), 10-Q/A (4), ARS (4), S-3 (4), 3/A (3), 8-K/A (3), DRS (3), NT 10-Q (3), SCHEDULE 13G (3), 4/A (2), 5 (2), NT 10-K (2), RW (2), S-3/A (2), 10-K/A (1), 424B4 (1), 8-A12B (1), CERT (1), DRSLTR (1), FWP (1), POS AM (1), POS EX (1), S-3MEF (1), SC 13D (1), SCHEDULE 13G/A (1)

  • Latest filingsAnnual report (10-K) Mar 30, 2026
    Quarterly report (10-Q) Aug 14, 2026
    Proxy statement (DEF 14A) Apr 29, 2026
    Latest 8-K (8-K) Aug 18, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, par value $0.001 per shareGNPXNasdaq

From the cover page of the 10-K filed Mar 30, 2026 (Section 12(b) of the Exchange Act).5

Risk factors and legal proceedings

The risks Genprex, Inc. names in Item 1A of its 10-K filed Mar 30, 2026: 71 risks under these headings, as written.5

  • Risks Related to Our Operations and Need for Additional Capital
  • We will require substantial additional funding, which may not be available to us on acceptable terms, or at all, and, if not so available, may require us to delay, limit, reduce or cease our operations.
  • Our recurring losses from operations have raised substantial doubt regarding our ability to continue as a going concern.
  • We have never been profitable, we have no products approved for commercial sale, and to date we have not generated any revenue from product sales. As a result, our ability to reduce our losses and reach profitability is unproven, and we may never achieve or sustain profitability.
  • We have a limited operating history and we expect a number of factors to cause our operating results to fluctuate on an annual basis, which may make it difficult to predict our future performance.
  • Our ability to utilize our net operating loss carryforwards may be limited, resulting in income taxes sooner than currently anticipated.
  • Risks Related to Development and Commercialization of Our Current and Future Product Candidates
  • Our success depends greatly on the success of our development of REQORSA for the treatment of NSCLC and SCLC, and our other product candidates, including GPX-002 for the treatment of diabetes.
  • The biopharmaceutical industry is subject to extensive regulatory obligations and policies that may be subject to change, including due to judicial challenges.
  • If we are unable to secure contract manufacturers with capabilities to produce the products that we require, we could experience delays in conducting our planned clinical trials.
  • Negative public opinion and increased regulatory scrutiny of gene therapy and genetic research may damage public perception of our current and potential product candidates or adversely affect our ability to conduct our business or obtain regulatory approvals for our current and potential product candidates.
  • Conducting successful clinical studies may require the enrollment of large numbers of patients, and suitable patients may be difficult to identify and recruit.
The other 60 risks
  • Delays in the commencement, enrollment and completion of clinical trials could result in increased costs to us and delay or limit our ability to obtain regulatory approval for REQORSA and other current or future product candidates.
  • Fast track designation of our products by FDA and designation under any other FDA expedited development program may not actually lead to a faster development or regulatory review or approval process, nor will it assure FDA approval of our product candidates.
  • We may not be able to obtain or maintain orphan drug designation or exclusivity for our product candidates.
  • A product candidate can fail at any stage of preclinical and clinical development.
  • REQORSA®, GPX-002, and any other product candidate we advance through clinical trials may not have favorable results in later clinical trials or receive regulatory approval. Even if we complete the necessary clinical trials, we cannot predict when, or if, we will obtain regulatory approval to commercialize our product candidates, and the approval may be for a narrower indication than we seek.
  • Even if we obtain regulatory approval of our current and future product candidates, the products may not gain market acceptance among physicians, patients, hospitals, treatment centers, third-party payors and others in the medical community.
  • REQORSA®, GPX-002, and other current or future product candidates may have undesirable side effects that may delay or prevent marketing approval, or, if approval is received, require them to be taken off the market, require them to include safety warnings or otherwise limit their sales.
  • If a product liability claim is successfully brought against us for uninsured liabilities, or such claim exceeds our insurance coverage, we could be forced to pay substantial damage awards that could materially harm our business.
  • Security breaches and other disruptions could compromise our information and expose us to liability, which would cause our business and reputation to suffer.
  • We face risks related to health epidemics and outbreaks or other widespread health crises which could significantly disrupt our preclinical studies and clinical trials. Any future disease outbreak, epidemic or pandemic, could disrupt our clinical trials and supply chain and materially adversely affect our business and operations.
  • We face competition from other biotechnology and pharmaceutical companies, particularly those that are gene therapy companies, and our operating results will suffer if we fail to compete effectively.
  • Risks Related to Regulatory Approval and Marketing of Our Current and Future Product Candidates and Other Legal Compliance Matters
  • We cannot provide assurance that REQORSA, GPX-002, or any of our other current or future product candidates will receive regulatory approval, and without regulatory approval we will not be able to market them.
  • Even if we obtain regulatory approval for our product candidates, our products will remain subject to regulatory oversight.
  • If the FDA does not find the manufacturing facilities of our current or future contract manufacturers acceptable for commercial production, we may not be able to commercialize REQORSA, GPX-002, or any of our other current or future product candidates.
  • We may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws and other federal and state healthcare laws, and the failure to comply with such laws could result in substantial penalties. Our employees, independent contractors, consultants, principal investigators, CROs, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.
  • Coverage and reimbursement may be limited or unavailable in certain market segments for REQORSA, GPX-002, and our other current or future product candidates, if approved, which could make it difficult for us to sell REQORSA, GPX-002, and our other current or future product candidates profitably.
  • Concerns about gene therapy, genetic testing, and genetic research could result in new and/or additional government regulations and requirements that restrict or prohibit the processes we use or delay or prevent the regulatory approval of our current and potential product candidates.
  • Healthcare legislative reform measures may have a material adverse effect on our business and results of operations.
  • We are subject to a variety of risks associated with international operations which could materially adversely affect our business.
  • If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.
  • Risks Related to Our Dependence on Third Parties
  • We may not be successful in establishing and maintaining development and commercialization collaborations, which could adversely affect our ability to develop our current and future product candidates and our financial condition and operating results could be adversely affected.
  • We rely, in part, and expect to continue to rely, in part, on third parties to conduct, supervise and monitor our clinical trials, and if these third parties perform in an unsatisfactory manner, it may harm our business.
  • Changes in the U.S. political and regulatory environment could affect availability of government funding that we or our third party collaborators may rely on, which could negatively impact the development of our product candidates.
  • We rely, and expect to continue to rely, on third parties to distribute, manufacture and perform release testing for our current and future product candidates and other key materials and if such third parties do not carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approvals for our product candidates.
  • We have completed and may in the future complete related party transactions that were not and may not be conducted on an arm’s length basis.
  • Disruptions in the global economy and supply chains may have a material adverse effect on our business, financial condition and results of operations.
  • Risks Related to Our Intellectual Property
  • If we fail to comply with obligations pursuant to our license agreements, we could lose intellectual property and other rights that are important to our business; if we fail to obtain licenses to advance our research and development that may be required we may be unable to develop the affected product exclusively, on acceptable terms or at all.
  • The intellectual property rights we have licensed from MD Anderson and the University of Pittsburgh are subject to the rights of the U.S. government.
  • If we are unable to protect our intellectual property rights or if our intellectual property rights are inadequate for our technology and product candidates, our competitive position could be harmed.
  • Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts.
  • We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through acquisitions and in-licenses.
  • Confidentiality agreements with employees and others may not adequately prevent disclosure of trade secrets and other proprietary information and may not adequately protect our intellectual property.
  • Our reliance on third parties may require us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.
  • We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful.
  • Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
  • Issued patents covering our product candidates could be found invalid or unenforceable if challenged in court.
  • We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.
  • We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.
  • Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.
  • We have in the past and may again in the future have trademark applications in the United States and/or certain other countries, and failure to secure these registrations could adversely affect our business; additionally, we may need to enforce our trademark rights against third parties and expend significant resources to enforce such rights against infringement.
  • We may not be able to protect our intellectual property rights throughout the world.
  • Risks Related to Employee Matters and Managing Growth
  • We have no sales, marketing or distribution experience and we will have to invest significant resources to develop those capabilities or enter into acceptable third-party sales and marketing arrangements.
  • We may not be able to manage our business effectively if we are unable to attract and retain key personnel and consultants.
  • We may use our financial and human resources to pursue a particular research program or product candidate and fail to capitalize on programs or product candidates that may be more profitable or for which there is a greater likelihood of success.
  • If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks.
  • Risks Related to our Securities
  • The market price of our common stock may be highly volatile, and you may lose all or part of your investment.
  • An active, liquid and orderly market for our common stock may not be sustained, and you may not be able to sell your common stock.
  • We are currently listed on The Nasdaq Capital Market. If we fail to maintain compliance with the continued listing requirements of Nasdaq, our common stock may be delisted and the price of our common stock and our ability to access the capital markets could be negatively impacted.
  • Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.
  • Failure to maintain effective internal control over our financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act of 2002, as amended (“Sarbanes-Oxley Act”) could cause our financial reports to be inaccurate.
  • We have no intention of declaring dividends in the foreseeable future.
  • Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall.
  • Future sales and issuances of our securities could result in additional dilution of the percentage ownership of our stockholders and could cause our share price to fall.
  • If securities or industry analysts do not publish research or reports about us, or if they adversely change their recommendations regarding our common stock, then our stock price and trading volume could decline.
  • Certain provisions in our organizational documents could enable our board of directors to prevent or delay a change of control.
  • Our Amended and Restated Certificate of Incorporation, as amended, and Amended and Restated Bylaws, as amended, contain an exclusive forum provision with respect to certain actions which may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable and discourage lawsuits against us or our current or former directors or officers and/or stockholders in such capacity.
  • General Risk Factors
  • Obligations associated with being a public company in the United States are expensive and time-consuming, and our management will be required to devote substantial time to compliance matters.
  • Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.
  • We may be at risk of securities class action litigation.

Legal proceedings

From time to time, we may be involved in legal proceedings that arise during the ordinary course of business. Although the results of legal proceedings cannot be predicted with certainty, we do not currently have any pending litigation to which we are a party or to which our property is subject that we believe to be material. Regardless of the outcome, litigation can be costly and time consuming, and it can divert management’s attention from important business matters and initiatives, negatively impacting our overall operations.

The opening of Item 3, Legal Proceedings.5

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
    SEC EDGAROther events
  31. 31
  32. 32
    SEC EDGAROther events
  33. 33
  34. 34
  35. 35
    SEC EDGAROther events
  36. 36
  37. 37
  38. 38
    SEC EDGAROther events
  39. 39
    SEC EDGAROther events
  40. 40
    SEC EDGAROther events
  41. 41
    SEC EDGAROther events
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48